GRI GRI Bio, Inc.

-

GRI Bio Beat Consensus Estimates

Friday, November 13, 2026 · 12:00 AM ET

GRI Bio (GRI) reported a loss of $0.69 per share on revenue of $0.00 million for the third quarter ended September 2026. The consensus estimate was a loss of $0.84 per share. The company beat consensus estimates by 17.86%.

GRI Bio Inc. is a clinical stage biopharmaceutical company which focused on fundamentally changing the way inflammatory, fibrotic and autoimmune diseases are treated. GRI Bio Inc., formerly known as Vallon Pharmaceuticals Inc., is based in PHILADELPHIA, PA.

Earnings Whisper Grade
Power Rating
Reported Earnings
($0.69)
Earnings Whisper®
—
Consensus Estimate
($0.84)
Earnings Surprise
Earnings Growth46.1 %
Reported Revenue
—
Revenue Estimate
—
Revenue Surprise
Revenue Growth—

*Reported earnings and revenue figures shown above, and any guidance given, are preliminary and may be updated upon further review.*